Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification of share transactions and does not contain financial performance data.
Material Changes
On January 31, 2006, Abacus (GSK) Trustees Limited, acting as trustee for the GlaxoSmithKline Employee Trust ("the GSK Trust"), transferred 4,100 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The Company was advised of these transactions on February 1, 2006.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The GSK Trust is identified as a discretionary trust where all current and former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. Three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) hold interests in the shares held by the GSK Trust in the same capacity as other employees.
Key Facts for Investor Verification
- 4,100 Ordinary Shares were transferred from the GSK Trust to employee plan participants on January 31, 2006.
- The transaction was reported under Disclosure Rule 3.1.4R(1)(b).
- Three specific directors have an interest in the GSK Trust shares alongside other employees.
- No financial performance metrics are included in this specific filing.